Since February 1988
About
OTSUKA PAKISTAN LIMITED
Otsuka Pakistan Limited was incorporated in February 1988 and commenced commercial production of intravenous solutions in September 1989 at its factory in Hub, Balochistan. OPL’s current activities are mainly focused on the manufacturing of I.V. Solutions and marketing them effectively to remain in the lead both in quality and quantity.
Intravenous Solution
Intravenous (IV) fluids are infused to maintain fluid balance, replace fluid losses, and treat electrolyte imbalances.
Nutraceutical Products
ORTie (oral rehydration therapy) is a special combination of dry salts and Vitamin C to be mixed with safe water. It is an advanced formula (low osmolar) according to WHO guidelines
Medical Devices
It improves blood flow to the heart muscle and relieves symptoms (usually chest pain). These are used depending on certain features of the artery blockage.
News & Events
A Sign of Japanese Commitment to Better Health
We take this responsibility seriously, and are appreciative of the many families and care givers who entrust us to help them on their journey.
-
We Welcome Mr. Moin ur Rehman as the Company’s new CEO effective from 28th February 2024
-
Re-opening of Line-II production after successful installation of machinery w.e.f. July 10, 2023
-
Nutraceutical Plant - Inauguration 15, March 2023
-
Mrs Navin Salim Merchant, Independent Director of the company has successfully completed her SECP approved Director Training Program from December 10th to 13th 2019
-
Otsuka launches new molecule in Gastroenterology segment for Gastritis and Gastric Ulcers
-
OPL Launched Mucosta (Rebamipide) 100mg tablets - anti-gastritis and anti-gastric ulcer agent in Pakistan
-
ACCA Approved Employer Certificate 2018 received by the CEO of OPL, Mr. Hanif Sattar on behalf of the Company.
-
ACCA Approved Employer 2017 –Trainee Development, Gold for Otsuka Pakistan Limited
-
The shareholders’ factory visit had been performed successfully on Tuesday, January 23, 2018
-
Notices to Shareholders
-
By striving to think differently, by challenging established ways of thinking, and by exploring paths of discovery that nobody else has thought of, Otsuka will continue to push the
-
The medical devices unit took yet another initiative by entering into “Orthopedic Implants market” through the launch of Microport Orthopedic Knee Implants.
-
Pan-Amin G Silver Jubilee26/07/23
-
UBiT Jang Forum-30-10-202213/02/23
-
UBiT in the Dow Lab - June 202215/07/22
-
UBiT Launch Event - Jan 1st, 201929/11/21
-
OTSUFLOX (Ciprofloxacin – 200MG/100ml IV Infusion)17/05/21
-
Corporate Briefing - Presented By CEO on October 22,201914/01/20
-
OPL Co-Create Activities with external Parties26/07/19
-
Otsuka 100 Years Celebration in 201927/04/19
-
OPL Launched OTSUMOL (Paracetamol - 1G/100ml IV Infusion) - 22 April 201926/04/19
-
Tree Plantation at OPL Head Office - 10th September 201810/09/18
-
OPL’s DISTRIBUTORS CONFERENCE-201804/05/18
-
During first quarter 2017 OPL held series of its distributors’ conferences area wise all over Pakistan, there were over 90 distributors from all parts of Pakistan invited at Multan, Lahore, Rawalpindi, Peshawar, Sukkur, Hyderabad, Karachi and Quetta.26/01/18
-
Closing ceremony of Otsuka Welfare Clinic31/12/17
-
In September 2017 the medical devices unit took yet another initiative by entering into “Orthopedic Implants market” through the launch of Microport Orthopedic Knee Implants i.e. Evolution Medial-Pivot Knee System in Pakistan.26/09/17